| Identification | Back Directory | [Name]
INDOMETHACIN SODIUM | [CAS]
7681-54-1 | [Synonyms]
osmosin
sodiumindomethacin
IndoMetacine sodiuM
INDOMETHACIN SODIUM
IndoMethacin sodiuM salt
Sodium 2-(1-(4-chlorobenzoyl)
sodium 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-ac...
sodium1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indole-3-acetate
sodium:2-[1-(4-chlorobenzoyl)-5-methoxy-2-methylindol-3-yl]acetate
1-(p-chlorobenzoyl)-5-methoxy-2-methyl-indole-3-aceticacisodiumsalt
1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1h-indole-3-aceticacisodiumsalt
1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid sodium salt
1H-Indole-3-acetic acid, 1-(4-chlorobenzoyl)-5-Methoxy-2-Methyl-, sodiuM salt | [EINECS(EC#)]
231-670-4 | [Molecular Formula]
C19H15ClNNaO4 | [MDL Number]
MFCD01939655 | [MOL File]
7681-54-1.mol | [Molecular Weight]
379.77 |
| Chemical Properties | Back Directory | [storage temp. ]
Sealed in dry,Room Temperature | [form ]
Powder | [InChI]
InChI=1S/C19H16ClNO4.Na/c1-11-15(10-18(22)23)16-9-14(25-2)7-8-17(16)21(11)19(24)12-3-5-13(20)6-4-12;/h3-9H,10H2,1-2H3,(H,22,23);/q;+1/p-1 | [InChIKey]
JMHRGKDWGWORNU-UHFFFAOYSA-M | [SMILES]
C12C=CC(OC)=CC=1C(=C(C)N2C(=O)C1C=CC(Cl)=CC=1)CC([O-])=O.[Na+] |
| Hazard Information | Back Directory | [Description]
Indomethacin sodium is a potent, orally active COX1/2 inhibitor with IC50 values of 18 nM and 26 nM for COX-1 and COX-2, respectively. Indomethacin sodium has anticancer activity and anti-infective activity. Indomethacin sodium can be used for cancer, inflammation and viral infection research. | [Uses]
Anti-inflammatory. | [Brand name]
Indocin (Ovation). | [in vivo]
Indomethacin (Indometacin) sodium (0.01-10 mg/kg; p.o.; for 3 hours; male Sprague-Dawley rats) induces paw oedema and hyperalgesmeasurement dose-dependently reversed carrageenan-induced hyperalgesia[1].
Indomethacin (Indometacin) sodium (10 mg/mL; p.o.; daily, for 29 days; male C57BL/6J mice) inhibits tumor growth in vivo[2]. | Animal Model: | Male Sprague-Dawley rats[1] | | Dosage: | 0.01-10 mg/kg | | Administration: | Oral administration; for 3 hours | | Result: | Inhibited the carrageenan-induced rat paw oedema (ED50=2.0?mg/kg) and hyperalgesia (ED50=1.5?mg/kg) in a dose-dependent manner. |
| Animal Model: | Male C57BL/6J mice[2] | | Dosage: | 10 mg/mL | | Administration: | Oral administration; daily, for 29 days | | Result: | Delayed the onset of tumor growth and the initial growth rate of the footpad tumors. |
| [IC 50]
COX-1: IC50 = 0.1 μM (sheep); Cox-1: IC50 = 1.67 μM (human);
COX-2: IC50 = 6 μM (sheep); Cox-2: IC50 = 24.6 μM (human) |
|
|